![Tracey McCain](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 981 313 $ al 30/06/2026
Tracey L.
McCain is currently an Independent Director at Kiniksa Pharmaceuticals Ltd. since 2018, an Independent Director at Kiniksa Pharmaceuticals International Plc since 2024, and a Trustee at Dana-Farber Cancer Institute, Inc. Former roles include Independent Director at ImmunoGen, Inc. from 2021 to 2024, Secretary, Chief Legal & Compliance Officer at Blueprint Medicines Corp.
from 2016 to 2025, Senior Vice President & Head-Legal at Genzyme Therapeutics Ltd. in 2016, General Counsel at Genzyme Corp.
from 1997 to 2016, and Associate at Palmer & Dodge LLP.
Education includes an undergraduate degree from the University of Pennsylvania in 1989 and a graduate degree from Columbia Law School in 1992.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
0,03 % | 29/05/2026 | 15.345 ( 0,03 % ) | 981 313 $ | 30/06/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
Kiniksa Pharmaceuticals Ltd.
 Kiniksa Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops and delivers therapeutic medicines for patients suffering from cardiovascular diseases | Director/Miembro de la Junta | 01/02/2018 |
Dana-Farber Cancer Institute, Inc.
 Dana-Farber Cancer Institute, Inc. Hospital/Nursing ManagementHealth Services Provides treatment to cancer patients | Director/Miembro de la Junta | - |
| Empresas | Cargo | Fin |
|---|---|---|
| BLUEPRINT MEDICINES CORPORATION | Oficial de Cumplimiento | 01/10/2025 |
| IMMUNOGEN, INC. | Director/Miembro de la Junta | 12/02/2024 |
Genzyme Therapeutics Ltd.
 Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Consejero General | 02/09/2016 |
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Consejero General | 01/09/2016 |
Palmer & Dodge LLP
 Palmer & Dodge LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 9 |
|---|---|
ImmunoGen, Inc.
 ImmunoGen, Inc. BiotechnologyHealth Technology Develops anticancer therapeutics | Health Technology |
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Dana-Farber Cancer Institute, Inc.
Dana-Farber Cancer Institute, Inc. Hospital/Nursing ManagementHealth Services Provides treatment to cancer patients | Health Services |
University of Pennsylvania
 University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Palmer & Dodge LLP
Palmer & Dodge LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Commercial Services |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Health Technology |
Columbia Law School
 Columbia Law School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Blueprint Medicines Corp.
 Blueprint Medicines Corp. BiotechnologyHealth Technology Develops cancer therapies that harness the growing understanding of the molecular blueprint of cancer | Health Technology |
Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops and delivers therapeutic medicines for patients suffering from cardiovascular diseases | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
Elige MarketScreener 
